Sign In
Buy MBRX
$2.46
+0 (+0%)
At Close: Jun 03, 2026
Moleculin Announces Reverse Stock Split
09:00am, Wednesday, 26'th Nov 2025
HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certif
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
08:36am, Thursday, 13'th Nov 2025
Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response activity tracking within expected range
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
08:37am, Wednesday, 12'th Nov 2025
Preclinical research to be conducted at the University of North Carolina at Chapel Hill (UNC) Annamycin will be used in conjunction with novel agents and modalities Preclinical studies indicate Anna
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
08:40am, Thursday, 30'th Oct 2025
HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
08:35am, Wednesday, 29'th Oct 2025
HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
08:00am, Thursday, 23'rd Oct 2025
Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
08:35am, Thursday, 25'th Sep 2025
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidate
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 17'th Sep 2025
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
08:45am, Tuesday, 09'th Sep 2025
European expansion in September across Georgia, Italy, Lithuania, Poland, Romania, Spain, and US 13 subjects recruited (treated, enrolled, or screened) Forecasts total recruitment of 20 or more subjec
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
08:30am, Monday, 08'th Sep 2025
Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.
Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds
08:30am, Thursday, 28'th Aug 2025
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
09:15am, Thursday, 14'th Aug 2025
– Live video webcast on Wednesday, August 20 th at 2:00 PM ET HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
08:05am, Wednesday, 13'th Aug 2025
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial - 20+ additional clinical sites in Europe and the US expected to begin recruitment by the end of Q3
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
08:40am, Wednesday, 06'th Aug 2025
Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
08:35am, Wednesday, 30'th Jul 2025
– New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical
